查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1594606

以体学为基础的临床试验市场：按阶段、研究设计、适应症 - 2025-2030 年全球预测

Omics-Based Clinical Trials Market by Phase (Phase I, Phase II, Phase III), Study Design (Expanded Access Studies, Interventional Studies, Observational Studies), Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年基于体学的临床试验市场价值为301亿美元，预计到2024年将达到325.1亿美元，复合年增长率为8.39%，到2030年将达到529.2亿美元。

基于体学的临床试验是精准医学的关键组成部分，它整合了基因组学、蛋白质组学、代谢体学和其他体学技术，根据每个患者独特的生物学特征量身定制治疗方案。对此类临床试验的需求是由于对可以提高疗效并最大限度地减少副作用的个人化治疗的需求不断增长而推动的。它应用于药物开发的各个阶段，从生物标记发现到治疗反应的患者分层。最终用途包括製药公司、生物技术公司和学术研究机构，所有这些公司都在利用体学资料来改善临床结果。市场成长受到高通量测序、资料分析技术进步以及人工智慧在分析复杂资料集不断扩大的作用的影响。此外，研究机构和製药公司之间为加速药物发现而加强的合作研究也支持了市场扩张。然而，资料挑战之一是与体学资料收集和分析体学的高成本，再加上资料隐私问题和整合多组体学资料集的复杂性，这是昂贵的。资料处理标准化有限也会影响试验的一致性和可重复性。在这个快速发展的市场中，有开发具有成本效益的资料分析平台和个人化治疗解决方案的机会，特别是在体学中显示出巨大潜力的肿瘤学领域。对强大的生物资讯工具的投资和区域监管协调的努力将支持市场成长。成功的导航需要采用灵活的技术整合方法，同时确保病患资料安全和道德标准。公司可以透过专注于提高基于体学的诊断和治疗的准确性和速度来进行创新。在罕见疾病和遗传疾病等利基应用中，体学可以改变游戏规则并提供富有洞察力的商机。总体而言，基于体学的临床试验市场复杂但前景广阔，具有巨大的创新和专业化潜力。

主要市场统计
基准年[2023] 301亿美元
预测年份 [2024] 325.1亿美元
预测年份 [2030] 529.2亿美元
复合年增长率（%） 8.39%

市场动态：针对快速发展的基于体学的临床试验市场揭示的关键市场洞察

基于体学的临床试验市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 加大医药研发领域投入
    • 各种慢性疾病的全球盛行率和负担不断增加
    • 对个人化医疗和癌症临床试验的日益关注
  • 市场限制因素
    • 基于体学的临床试验产品高成本
  • 市场机会
    • 消费者对多组体学解决方案的认识与采用不断增强
    • 全球併购活动激增
  • 市场挑战
    • 有效资料分析的问题

波特的五力：驾驭基于体学的临床试验市场的策略工具

波特的五力架构是了解基于体学的临床试验市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解基于体学的临床试验市场的外部影响

外部宏观环境因素在塑造基于体学的临床试验市场的绩效动态方面发挥关键作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解以体学为基础的临床试验市场的竞争格局

基于体学的临床试验市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵组体学临床试验市场供应商绩效评估

FPNV定位矩阵是评估基于体学的临床试验市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製基于体学的临床试验市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，基于体学的临床试验市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 加大医药研发领域投入
      • 全球各种慢性病的盛行率和负担不断增加
      • 更重视个人化医学和肿瘤学试验
    • 抑制因素
      • 基于体学的临床试验产品高成本
    • 机会
      • 消费者对多组体学解决方案的认识与采用不断增强
      • 全球併购活动激增
    • 任务
      • 有效资料分析的问题
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章以体学为基础的临床试验市场分阶段

  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第七章 以体学为基础的临床试验市场研究设计

  • 扩大访问研究
  • 干预研究
  • 观察性研究

第八章以体学的临床试验市场（按适应症）

  • 心臟病学
  • 中枢神经系统疾病
  • 遗传疾病
  • 免疫学
  • 肿瘤学
  • 呼吸系统疾病
  • 皮肤病

第九章美洲基于体学的临床试验市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太组体学临床试验市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲基于体学的临床试验市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Complete Omics, Inc.
  • Covance Inc.
  • Danaher Corporation
  • Eli Lilly and Company
  • ICON Plc
  • Laboratory Corporation of America Holdings
  • Merck & Co. Inc.
  • Mission Bio, Inc.
  • NeoGenomics Laboratories, Inc.
  • Novo Nordisk A/S
  • Parexel International Corporation
  • Pfizer, Inc.
  • Rebus Biosystems, Inc.
  • SGS SA
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-3A2E844FD3E0

The Omics-Based Clinical Trials Market was valued at USD 30.10 billion in 2023, expected to reach USD 32.51 billion in 2024, and is projected to grow at a CAGR of 8.39%, to USD 52.92 billion by 2030.

Omics-based clinical trials represent a crucial component of precision medicine, integrating genomics, proteomics, metabolomics, and other omics technologies to tailor therapies towards individual patients' unique biological profiles. The necessity for such trials is driven by the increasing demand for personalized medical treatments, which can improve efficacy and minimize side effects. They are applied across various stages of drug development, from biomarker discovery to patient stratification in treatment responses. End-use scope includes pharmaceuticals, biotechnology companies, and academic research institutions, all leveraging omics data to enhance clinical outcomes. Market growth is influenced by technological advancements in high-throughput sequencing, data analytics, and the expanding role of AI in analyzing complex datasets. Increasing collaborations between research institutions and pharmaceutical companies to accelerate drug discovery also propel market expansion. However, one of the significant challenges is the high cost associated with omics data collection and analysis, coupled with data privacy concerns and the complexity of integrating multi-omics datasets. Limited standardization in data handling also affects trial consistency and reproducibility. Within this rapidly evolving market, opportunities lie in the development of cost-effective data analytics platforms and personalized therapeutic solutions, especially in oncology where omics have shown considerable promise. Investment in robust bioinformatics tools and efforts towards regulatory harmonization across regions can bolster market growth. Successful navigation involves adopting an agile approach to technological integration while ensuring patient data security and ethical standards. Companies can innovate by focusing on improving the accuracy and speed of omics-based diagnostics and treatments. Insightful opportunities await in niche applications like rare diseases and genetic disorders, where omics can make a significant difference. Overall, the market for omics-based clinical trials is complex yet promising, with a substantial capacity for innovation and specialization.

KEY MARKET STATISTICS
Base Year [2023] USD 30.10 billion
Estimated Year [2024] USD 32.51 billion
Forecast Year [2030] USD 52.92 billion
CAGR (%) 8.39%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Omics-Based Clinical Trials Market

The Omics-Based Clinical Trials Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising investment in the pharmaceutical research and development sector
    • Increasing prevalence and burden of various chronic diseases globally
    • Growing focus on personalized medicine and oncology trials
  • Market Restraints
    • High cost of omics-based clinical trials products
  • Market Opportunities
    • Upsurging consumer awareness and adoption of multi-omics solutions
    • Proliferation in the number of amalgamation activities across the globe
  • Market Challenges
    • Issues relating to effective data analysis

Porter's Five Forces: A Strategic Tool for Navigating the Omics-Based Clinical Trials Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Omics-Based Clinical Trials Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Omics-Based Clinical Trials Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Omics-Based Clinical Trials Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Omics-Based Clinical Trials Market

A detailed market share analysis in the Omics-Based Clinical Trials Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Omics-Based Clinical Trials Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Omics-Based Clinical Trials Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Omics-Based Clinical Trials Market

A strategic analysis of the Omics-Based Clinical Trials Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Omics-Based Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include Complete Omics, Inc., Covance Inc., Danaher Corporation, Eli Lilly and Company, ICON Plc, Laboratory Corporation of America Holdings, Merck & Co. Inc., Mission Bio, Inc., NeoGenomics Laboratories, Inc., Novo Nordisk A/S, Parexel International Corporation, Pfizer, Inc., Rebus Biosystems, Inc., SGS SA, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Omics-Based Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Phase, market is studied across Phase I, Phase II, Phase III, and Phase IV.
  • Based on Study Design, market is studied across Expanded Access Studies, Interventional Studies, and Observational Studies.
  • Based on Indication, market is studied across Cardiology, CNS Diseases, Genetic Diseases, Immunology, Oncology, Respiratory Diseases, and Skin Diseases.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising investment in the pharmaceutical research and development sector
      • 5.1.1.2. Increasing prevalence and burden of various chronic diseases globally
      • 5.1.1.3. Growing focus on personalized medicine and oncology trials
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of omics-based clinical trials products
    • 5.1.3. Opportunities
      • 5.1.3.1. Upsurging consumer awareness and adoption of multi-omics solutions
      • 5.1.3.2. Proliferation in the number of amalgamation activities across the globe
    • 5.1.4. Challenges
      • 5.1.4.1. Issues relating to effective data analysis
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Omics-Based Clinical Trials Market, by Phase

  • 6.1. Introduction
  • 6.2. Phase I
  • 6.3. Phase II
  • 6.4. Phase III
  • 6.5. Phase IV

7. Omics-Based Clinical Trials Market, by Study Design

  • 7.1. Introduction
  • 7.2. Expanded Access Studies
  • 7.3. Interventional Studies
  • 7.4. Observational Studies

8. Omics-Based Clinical Trials Market, by Indication

  • 8.1. Introduction
  • 8.2. Cardiology
  • 8.3. CNS Diseases
  • 8.4. Genetic Diseases
  • 8.5. Immunology
  • 8.6. Oncology
  • 8.7. Respiratory Diseases
  • 8.8. Skin Diseases

9. Americas Omics-Based Clinical Trials Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Omics-Based Clinical Trials Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Omics-Based Clinical Trials Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Complete Omics, Inc.
  • 2. Covance Inc.
  • 3. Danaher Corporation
  • 4. Eli Lilly and Company
  • 5. ICON Plc
  • 6. Laboratory Corporation of America Holdings
  • 7. Merck & Co. Inc.
  • 8. Mission Bio, Inc.
  • 9. NeoGenomics Laboratories, Inc.
  • 10. Novo Nordisk A/S
  • 11. Parexel International Corporation
  • 12. Pfizer, Inc.
  • 13. Rebus Biosystems, Inc.
  • 14. SGS SA
  • 15. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. OMICS-BASED CLINICAL TRIALS MARKET RESEARCH PROCESS
  • FIGURE 2. OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. OMICS-BASED CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. OMICS-BASED CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. OMICS-BASED CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. OMICS-BASED CLINICAL TRIALS MARKET DYNAMICS
  • TABLE 7. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY EXPANDED ACCESS STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY CNS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY GENETIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY SKIN DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 59. INDONESIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 62. JAPAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 65. MALAYSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 68. PHILIPPINES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 71. SINGAPORE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 74. SOUTH KOREA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 77. TAIWAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 80. THAILAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 83. VIETNAM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 90. DENMARK OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 93. EGYPT OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 96. FINLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 99. FRANCE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 102. GERMANY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 105. ISRAEL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 108. ITALY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 111. NETHERLANDS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 114. NIGERIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 117. NORWAY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 120. POLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 123. QATAR OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 126. RUSSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 129. SAUDI ARABIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 135. SPAIN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 138. SWEDEN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 141. SWITZERLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 144. TURKEY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED ARAB EMIRATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED KINGDOM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. OMICS-BASED CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 152. OMICS-BASED CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023